Lucid Diagnostics Inc
NASDAQ:LUCD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
US |
|
L
|
Lattice Semiconductor Corp
F:LTT
|
US |
|
X
|
XCure Corp
KOSDAQ:070300
|
KR |
|
E
|
Equites Property Fund Ltd
JSE:EQU
|
ZA |
|
T
|
Taewoong Co Ltd
KOSDAQ:044490
|
KR |
|
G
|
GH Research PLC
SWB:1KA
|
IE |
Intrinsic Value
Is LUCD undervalued or overvalued?
See the intrinsic value estimate for Lucid Diagnostics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Lucid Diagnostics Does
Lucid Diagnostics makes medical tests that help doctors look for precancerous changes in the esophagus before they turn into cancer. Its main product is a screening system built around a simple cell collection device and a lab test that checks those cells for signs of Barrett’s esophagus and esophageal precancer. The company sells this as a way to find disease earlier than a standard endoscopy in people with reflux symptoms or other risk factors.
- Headquarters
- United States of America US
- Employees
- 82
- IPO date
- Oct 14, 2021
Earnings Waterfall
Lucid Diagnostics Inc
The intrinsic value for Lucid Diagnostics Inc (LUCD) under the Base Case is hidden USD.
Compared with the current market price of 0.3901 USD, the stock appears hidden.